Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Investigation of cardiovascular risk 5-15 years after early or late-onset preeclampsia by adenosine stress Magnetic Resonance Imaging and non-invasive methods like retinal vessel analysis, skin measurement of advanced glycation end products, flow-mediated dilation or pulse wave analysis in comparison to women after healthy pregnancies.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Early-onset preeclampsia | Defined as preeclampsia that develops before 34 weeks of gestation | ||
| Late-onset preeclampsia | Defined as preeclampsia that develops after 34 weeks of gestation | ||
| Control | Healthy pregnancies, matched to early and late-onset cases |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Myocardial perfusion | Measured by adenosine stress Magnetic Resonance Imaging (ml/min/g) | Day 2 |
| Measure | Description | Time Frame |
|---|---|---|
| Cardiac fibrosis | Measured by Magnetic Resonance Imaging (g) | Day 2 |
| Immune cell phenotypes | Measured in isolated peripheral blood mononuclear cells |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Woman 5-15 years after pregnancy
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Kristin Kräker, PhD | Contact | +49 30 450540 328 | kristin.kraeker@charite.de |
| Name | Affiliation | Role |
|---|---|---|
| Anja Mähler, PhD | Charite University, Berlin, Germany | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Experimental and Clinical Research Center | Recruiting | Berlin | 13125 | Germany |
Individual participant data that underlie the results of reported articles (text, tables, figures, supplemental data) will be shared after deidentification.
Not provided
Beginning 9 months and ending 36 months following article publication.
Researchers who provide a methodologically sound proposal.
Not provided
Not provided
| ID | Term |
|---|---|
| D011225 | Pre-Eclampsia |
| ID | Term |
|---|---|
| D046110 | Hypertension, Pregnancy-Induced |
| D011248 | Pregnancy Complications |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Plasma, serum, peripheral blood mononuclear cells (PBMCs)
| Day 1 |
| Concentration of N-terminal prohormone of brain natriuretic peptide | Measured in serum (ng/l) | Day 1 |
| Concentration of brain natriuretic peptide | Measured in serum (ng/l) | Day 1 |
| Urinary protein | Measured in spot urine (mg) | Day 1 |
| Advanced glycation end products | Measured by skin autofluorescence (arbitrary units) | Day 1 |
| Body fat mass | Measured by bioimpedance analysis (%) | Day 1 |
| Body fat-free mass | Measured by bioimpedance analysis (%) | Day 1 |
| Hand grip strength | Measured by dynamometer (kg) | Day 1 |
| Systolic blood pressure | Mean of three consecutive blood pressure measurements (mmHg) | Day 1 |
| Diastolic blood pressure | Mean of three consecutive blood pressure measurements (mmHg) | Day 1 |
| Pulse wave velocity | Calculated by algorithm based on age and blood pressure values (m/s) | Day 1 |
| Flow-mediated dilation | Measured by brachial artery diameter (µm) | Day 1 |
| Reactive hyperemia index | Measured by finger plethysmography | Day 1 |
| Choroidal thickness | Measured with Optical Coherence Tomography (µm) | Day 1 |
| Macular volume | Measured with Optical Coherence Tomography (mm³) | Day 1 |
| Arterial dilation induced by retinal flicker stimulation | Measured with Dynamic Vessel Analyser (seconds) | Day 1 |
| Venous dilation induced by retinal flicker stimulation | Measured with Dynamic Vessel Analyser (seconds) | Day 1 |